5-aza-2'-Deoxycytidine Induces a RIG-I-Related Innate Immune Response by Modulating Mitochondria Stress in Neuroblastoma.
DNA methyltransferase inhibitor
double-stranded RNA
innate immune response
mitochondria
neuroblastoma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
19 08 2020
19 08 2020
Historique:
received:
31
07
2020
accepted:
15
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
1
5
2021
Statut:
epublish
Résumé
Neuroblastoma (NB) is one of the most common malignant solid tumors to occur in children, characterized by a wide range of genetic and epigenetic aberrations. We studied whether modifications of the latter with a 5-aza-2'-deoxycytidine (decitabine, Dac) DNA methyltransferase inhibitor can provide a therapeutic advantage in NB. NB cells with or without Dac preferentially induced a RIG-I-predominant innate immune response and cell apoptosis in SK-N-AS NB cells, significantly reduced the methylation level of the This study indicates that Dac effectively induces a RIG-I-related innate immune response and apoptotic signaling primarily in SK-N-AS NB cells by hypomethylating
Sections du résumé
BACKGROUND
Neuroblastoma (NB) is one of the most common malignant solid tumors to occur in children, characterized by a wide range of genetic and epigenetic aberrations. We studied whether modifications of the latter with a 5-aza-2'-deoxycytidine (decitabine, Dac) DNA methyltransferase inhibitor can provide a therapeutic advantage in NB.
METHODS
NB cells with or without
RESULTS
Dac preferentially induced a RIG-I-predominant innate immune response and cell apoptosis in SK-N-AS NB cells, significantly reduced the methylation level of the
CONCLUSIONS
This study indicates that Dac effectively induces a RIG-I-related innate immune response and apoptotic signaling primarily in SK-N-AS NB cells by hypomethylating
Identifiants
pubmed: 32824929
pii: cells9091920
doi: 10.3390/cells9091920
pmc: PMC7564572
pii:
doi:
Substances chimiques
Decitabine
776B62CQ27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Oncoimmunology. 2017 Apr 28;6(6):e1320626
pubmed: 28680756
Cancer Cell. 2012 Mar 20;21(3):430-46
pubmed: 22439938
J Clin Invest. 2014 Jan;124(1):40-6
pubmed: 24382388
FEBS J. 2014 Sep;281(17):3791-802
pubmed: 25051991
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6097-102
pubmed: 23479628
Pediatr Hematol Oncol. 2011 Mar;28(2):106-14
pubmed: 21214410
Cell Death Dis. 2018 Nov 7;9(11):1122
pubmed: 30405116
Int J Oncol. 2015 Apr;46(4):1710-20
pubmed: 25626059
Eur J Gastroenterol Hepatol. 2009 May;21(5):565-9
pubmed: 19282772
Am J Physiol Cell Physiol. 2005 Dec;289(6):C1466-75
pubmed: 16107504
Biochem Biophys Res Commun. 2004 Dec 24;325(4):1399-405
pubmed: 15555582
J Biol Chem. 2019 Apr 5;294(14):5396-5407
pubmed: 29622680
Int J Mol Sci. 2015 Jan 22;16(2):2472-96
pubmed: 25622259
Redox Biol. 2017 Oct;13:633-645
pubmed: 28818792
Clin Cancer Res. 2006 Dec 15;12(24):7347-52
pubmed: 17189406
Mol Pharm. 2014 Jun 2;11(6):1856-68
pubmed: 24824514
Transl Res. 2018 Dec;202:52-68
pubmed: 30165038
Oncogene. 2008 Jul 10;27(30):4221-32
pubmed: 18362892
Oncogene. 2008 Feb 28;27(10):1478-88
pubmed: 17724465
J Biomed Sci. 2011 Aug 23;18:65
pubmed: 21861882
Front Immunol. 2017 Nov 03;8:1473
pubmed: 29163537
Biochem J. 2009 Jan 1;417(1):1-13
pubmed: 19061483
RNA. 2019 Jun;25(6):713-726
pubmed: 30894411
Int J Cancer. 2012 Nov 15;131(10):2308-19
pubmed: 22362391
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
BMC Cancer. 2010 Jun 14;10:286
pubmed: 20546602
Anticancer Drugs. 1993 Dec;4(6):629-35
pubmed: 7507741
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
Apoptosis. 2012 Apr;17(4):335-48
pubmed: 22187010
Clin Cancer Res. 2006 Oct 1;12(19):5817-25
pubmed: 17020989
Respir Res. 2016 Sep 07;17(1):111
pubmed: 27604339
Cancer Res. 2005 Feb 1;65(3):828-34
pubmed: 15705880
Nature. 2018 Aug;560(7717):238-242
pubmed: 30046113
Curr Cancer Drug Targets. 2011 Feb;11(2):226-35
pubmed: 21158717
Biochem Pharmacol. 2012 Apr 1;83(7):858-65
pubmed: 22280814
Cell Differ Dev. 1989 Jun;27(1):47-55
pubmed: 2475229
BMC Biol. 2012 May 24;10:44
pubmed: 22626058
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Cell. 2015 Aug 27;162(5):974-86
pubmed: 26317466
Exp Mol Med. 2018 Apr 27;50(4):51
pubmed: 29700278
Epigenomics. 2015 Oct;7(7):1137-53
pubmed: 26067621